161 related articles for article (PubMed ID: 9225136)
1. Nasal calcitonin.
Silverman SL
Endocrine; 1997 Apr; 6(2):199-202. PubMed ID: 9225136
[TBL] [Abstract][Full Text] [Related]
2. Calcitonin.
Silverman SL
Am J Med Sci; 1997 Jan; 313(1):13-6. PubMed ID: 9001161
[TBL] [Abstract][Full Text] [Related]
3. Calcitonin.
Silverman SL
Endocrinol Metab Clin North Am; 2003 Mar; 32(1):273-84. PubMed ID: 12699303
[TBL] [Abstract][Full Text] [Related]
4. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
Binkley N; Bolognese M; Sidorowicz-Bialynicka A; Vally T; Trout R; Miller C; Buben CE; Gilligan JP; Krause DS;
J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
[TBL] [Abstract][Full Text] [Related]
5. Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis.
Body JJ
Bone; 2002 May; 30(5 Suppl):75S-79S. PubMed ID: 12008163
[TBL] [Abstract][Full Text] [Related]
6. Nasal salmon calcitonin blunts bone microstructure alterations in healthy postmenopausal women.
Rizzoli R; Sigaud A; Azria M; Herrmann FR
Osteoporos Int; 2015 Jan; 26(1):383-93. PubMed ID: 25566730
[TBL] [Abstract][Full Text] [Related]
7. Increase of axial and appendicular trabecular and cortical bone density in established osteoporosis with intermittent nasal salmon calcitonin therapy.
Peichl P; Rintelen B; Kumpan W; Bröll H
Gynecol Endocrinol; 1999 Feb; 13(1):7-14. PubMed ID: 10368793
[TBL] [Abstract][Full Text] [Related]
8. Effect of intermittent administration of 200 IU intranasal salmon calcitonin and low doses of 1alpha(OH) vitamin D3 on bone mineral density of the lumbar spine and hip region and biochemical bone markers in women with postmenopausal osteoporosis: a pilot study.
Kaskani E; Lyritis GP; Kosmidis C; Galanos A; Andypas G; Chorianopoulos K; Giagiosis A; Iliadou K; Karagianis A; Katsimichas K; Koskinas A; Matsouka K
Clin Rheumatol; 2005 Jun; 24(3):232-8. PubMed ID: 15647969
[TBL] [Abstract][Full Text] [Related]
9. The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures--an open label study.
Tóth E; Csupor E; Mészáros S; Ferencz V; Németh L; McCloskey EV; Horváth C
Bone; 2005 Jan; 36(1):47-51. PubMed ID: 15664001
[TBL] [Abstract][Full Text] [Related]
10. Calcitonin.
Silverman SL
Rheum Dis Clin North Am; 2001 Feb; 27(1):187-96. PubMed ID: 11285994
[TBL] [Abstract][Full Text] [Related]
11. Patient responsiveness to calcitonin salmon nasal spray: a subanalysis of a 2-year study.
Overgaard K; Lindsay R; Christiansen C
Clin Ther; 1995; 17(4):680-5. PubMed ID: 8565031
[TBL] [Abstract][Full Text] [Related]
12. [Clinical efficacy of treatment with salmon calcitonin, administered intranasally for 1 year, in stabilized postmenopausal osteoporosis].
Agnusdei D; Gonnelli S; Camporeale A; Batignani T; Nardi P; Ianes A; Gennari C
Minerva Endocrinol; 1989; 14(3):169-76. PubMed ID: 2695815
[TBL] [Abstract][Full Text] [Related]
13. Effect of different doses of nasal salmon calcitonin on bone mass.
Thamsborg G; Storm TL; Sykulski R; Brinch E; Nielsen HK; Sørensen OH
Calcif Tissue Int; 1991 May; 48(5):302-7. PubMed ID: 2054714
[TBL] [Abstract][Full Text] [Related]
14. Calcitonin and postmenopausal bone loss.
Reginster JY; Deroisy R; Lecart MP; Sarlet N; Fontaine MA; Albert A; Franchimont P
Exp Gerontol; 1990; 25(3-4):349-56. PubMed ID: 2226670
[TBL] [Abstract][Full Text] [Related]
15. Oral salmon calcitonin--pharmacology in osteoporosis.
Henriksen K; Bay-Jensen AC; Christiansen C; Karsdal MA
Expert Opin Biol Ther; 2010 Nov; 10(11):1617-29. PubMed ID: 20932224
[TBL] [Abstract][Full Text] [Related]
16. [Calcitonin].
Reginster JY
Rev Med Liege; 1996 Jan; 51(1):116-9. PubMed ID: 8701121
[No Abstract] [Full Text] [Related]
17. Early effect of nasal salmon calcitonin on the bone marker Crosslaps.
Ofluoglu D; Karadag-Saygi E; Canbulat C; Gunduz OH; Kul-Panza E; Akyuz G
Rheumatol Int; 2006 Feb; 26(4):288-91. PubMed ID: 15875189
[TBL] [Abstract][Full Text] [Related]
18. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 9. Calcitonin in the treatment of osteoporosis.
Siminoski K; Josse RG
CMAJ; 1996 Oct; 155(7):962-5. PubMed ID: 8837547
[TBL] [Abstract][Full Text] [Related]
19. Calcitonin and the treatment of osteoporosis.
Schneyer CR
Md Med J; 1991 Jun; 40(6):469-73. PubMed ID: 1861574
[TBL] [Abstract][Full Text] [Related]
20. Comparison of alendronate and intranasal calcitonin for treatment of osteoporosis in postmenopausal women.
Downs RW; Bell NH; Ettinger MP; Walsh BW; Favus MJ; Mako B; Wang L; Smith ME; Gormley GJ; Melton ME
J Clin Endocrinol Metab; 2000 May; 85(5):1783-8. PubMed ID: 10843152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
